CAPTRUST Financial Advisors’s Applied Genetic Technologies Corporation AGTC Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AGTC Stock Details AGTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,000	Closed	-$2K	–	4554
2022 Q2	$2K	Hold	3,000	–	–	﹤0.01%	4567
2022 Q1	$3K	Buy	3,000 +500	+20%	+$909	﹤0.01%	4426
2021 Q4	$5K	Hold	2,500	–	–	﹤0.01%	4121
2021 Q3	$8K	Sell	2,500 -500	-17%	-$1.78K	﹤0.01%	3768
2021 Q2	$12K	Buy	3,000 +2,500	+500%	+$10.4K	﹤0.01%	3467
2021 Q1	$3K	Buy	+500	New	+$2.59K	﹤0.01%	3962

Other funds holding AGTC

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAPTRUST Financial Advisors's AGTC Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Applied Genetic Technologies Corporation (AGTC) in Q3 2022, closing a stake of 3,000 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in AGTC in Q1 2021 and held it in 6 quarters. The position peaked at $12K in Q2 2021. 45 funds tracked by Wall St. Rank hold AGTC as of Q3 2022.

CAPTRUST Financial Advisors reported no remaining Applied Genetic Technologies Corporation position as of Q3 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 3,000 Applied Genetic Technologies Corporation shares in Q3 2022, an estimated $2K.
CAPTRUST Financial Advisors first reported a position in Applied Genetic Technologies Corporation in Q1 2021 and held it in 6 quarters.
CAPTRUST Financial Advisors's Applied Genetic Technologies Corporation position peaked at $12K in Q2 2021.
45 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.